Zai Lab Limited

Equities

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
18.04 USD +1.12% Intraday chart for Zai Lab Limited +4.16% -33.99%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading MT
Zai Lab Subsidiary to Borrow 250 Million Yuan from China Merchants Bank MT
Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing MT
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading MT
Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 CI
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis CI
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment MT
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro MT
Zai Lab's Cancer Drug Gets NDA Approval in China MT
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA CI
Zai Lab's Shares Rise After Q1 Beat MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
Top Premarket Gainers MT
Chart Zai Lab Limited
More charts
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.04 USD
Average target price
49.67 USD
Spread / Average Target
+175.33%
Consensus
  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. News Zai Lab Limited
  5. Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday